<DOC>
	<DOCNO>NCT02656329</DOCNO>
	<brief_summary>This event-driven Phase IIIb , multicentre , randomise , clinical study demonstrate efficacy AdreView™ image appropriately guide decision implantable cardioverter defibrillator ( ICD ) implantation , New York Health Association ( NYHA ) class II III heart failure patient 30 % ≤left ventricular ejection fraction ( LVEF ) ≤35 % % , particular , identify patient low risk sudden cardiac death would benefit , may suffer harm , implantation ICD device .</brief_summary>
	<brief_title>International Study Determine AdreView Heart Function Scan Can Used Identify Patients With Mild Moderate Heart Failure ( HF ) That Benefit From Implanted Medical Device</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Lugol 's solution</mesh_term>
	<mesh_term>3-Iodobenzylguanidine</mesh_term>
	<criteria>Patients ≥18 year age time date informed consent obtain . Female patient must premenarchal , surgically sterile ( documented bilateral oophorectomy and/or document hysterectomy ) , postmenopausal ( cessation menses 1 year ) , nonlactating , , childbearing potential , serum urine pregnancy test result know prior AdreView ( Iobenguane I123 Injection ) administration ) negative . Patients willing able comply study procedure sign date informed consent obtain studyprocedure carry . Heart failure NYHA class II III symptom , patient ischemic nonischemic heart disease , eligible ICD implantation per site 's standard practice . Heart failure NYHA class II III symptom , patient ischemic nonischemic heart disease , eligible ICD implantation per site 's standard practice . Nonischemic dilate cardiomyopathy ischemic heart disease least 3 month duration . 30 % ≤LVEF≤35 % , perform within 3 month time enrolment , measure radionuclide ventriculography , electrocardiogram [ ECG ] gate SPECT myocardial perfusion image [ MPI ] , magnetic resonance image [ MR ] , compute tomography [ CT ] , 3D 2D echocardiography [ Simpson 's multidisc method , Mmode echocardiography accept ] . In case LVEF measurement perform within 3 month enrolment , measurement perform least 40 day hospitalisation HF acute coronary syndrome ( include myocardial infarction ) , valid , method measurement accordance protocol image exam make available Sponsor digital format . In case several valid LVEF measurement available , close enrolment use inclusion determination . Clinically stable heart failure medical judgment investigator ( i.e . significant change medication , worsen symptom , unscheduled visit doctor 's office ) past 30 day hospitalisation heart failure acute coronary syndrome ( include myocardial infarction ) past 40 day . Reasonable expectation meaningful survival least 1 year . Patients exist ICD patient indication ICD implantation secondary prevention sudden cardiac death . Hospitalisation HF acute coronary syndrome previous 40 day . Patients cardiac resynchronisation therapy ( CRT ) plan indicate . Other indication placement device ( sustain ventricular tachycardia , resuscitate sudden death , need atrioventricular pacing ) . NYHA class I class IV symptom time study entry . Patient chronic renal insufficiency define serum creatinine ≥ 3 mg/dl ( 265.2 µmol/L ) . American College CollegeAmerican Heart Association ( ACCAHA ) class III class IV ( unstable ) angina . Known suspected hypersensitivity/allergy Iobenguane excipients Adreview ( Iobenguane I131 injection ) . Patient pregnant plan become pregnant within 2 week AdreView ( Iobenguane I123 Injection ) administration . Patient use medication 2 week AdreView ( Iobenguane I123 Injection ) could interfere test : e.g . limited amitriptyline derivative , imipramine derivative , antidepressant drug know suspected inhibit norepinephrine transporter , antihypertensives deplete norepinephrine store inhibit reuptake , sympathomimetic amine cocaine . Patients medical condition could interfere AdreView test ( e.g . limited leave ventricular assist device ( LVAD ) , prior heart transplant ) . Patients participate clinical study involve drug device within 30 day prior study entry patient participate clinical study . Patients serious noncardiac medical condition associate significant elevation plasma catecholamine , include pheochromocytoma . Patients clinical diagnosis ( treat ) Parkinson 's disease Multiple System Atrophy . The patient participate research study use ionize radiation previous 12 month . The patient participate research study use ionize radiation previous 12 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Heart Failure ( HF )</keyword>
	<keyword>Single photon emission computer tomography scan ( SPECT )</keyword>
	<keyword>Implantable cardioverter defibrillator ( ICD )</keyword>
	<keyword>Left Ventricular ejection fraction ( LVEF )</keyword>
	<keyword>New York Health Association ( NYHA )</keyword>
	<keyword>Metaiodobenzylguanidine ( mIBG )</keyword>
	<keyword>123I-iobenguane</keyword>
	<keyword>Heart-to-mediastinal ratio ( H/M )</keyword>
	<keyword>ADMIRE-ICD ( AdreView Myocardial Imaging Risk Evaluation - Implantable Cardioverter Defibrillator</keyword>
	<keyword>All-cause mortality</keyword>
	<keyword>Cardiac mortality</keyword>
</DOC>